GlaxoSmithKline's fifth round of price cuts since 1997 includes 14 HIV drugs reduced by an average of 21%. The biggest reduction is a 40% cut in the price of Ziagen, a first and second line AIDS treatment. With the use of compulsory licenses becoming more frequent among developing countries, GSK will hope that such price cuts appease governments and prevent their patents being bypassed.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions